<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02680756</url>
  </required_header>
  <id_info>
    <org_study_id>ST10-01-304</org_study_id>
    <nct_id>NCT02680756</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD</brief_title>
  <official_title>A Phase 3b, Randomized, Controlled, Multicentre Study With Oral Ferric Maltol (Feraccru) or Intravenous Iron (Ferric Carboxy Maltose; FCM), for the Treatment of Iron Deficiency Anaemia in Subjects With Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shield Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shield Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of ferric maltol and intravenous iron
      (IVI) Ferric Carboxy Maltose in the treatment of iron deficiency anaemia (IDA) and subsequent
      maintenance of haemoglobin in subjects with Inflammatory Bowel Disease (IBD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 3b, randomized, controlled, multicentre study with oral ferric maltol or intravenous
      iron (FCM), for the treatment of iron deficiency anaemia in subjects with inflammatory bowel
      disease.

      Approximately 242 eligible subjects will be randomised (1:1) to receive one of the following
      treatments for the duration of the study treatment period (52 weeks):

        -  Oral ferric maltol, 30 mg capsule bid.

        -  Intravenous iron (ferric carboxy maltose) as per SPC

      In the FCM arm IV iron treatment will be repeated if the subject is iron deficient at any of
      the study visits.

      Subject participation in the study will consist of 3 periods:

        -  Screening: Up to 14 days

        -  Randomised Treatment: 52 weeks

        -  Post-treatment safety follow-up: 14 days after study medication discontinuation

      Primary efficacy and safety of ferric maltol and Intravenous iron (ferric carboxy maltose)
      will be evaluated after the first 12 weeks.

      End of study evaluations will occur at Week 52 or premature discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb (&gt;12g/dL Women, &gt;13g/dL Men) at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (&gt;12g/dL women, &gt;13g/dL men) at Week 12 results per protocol (PP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb (&gt;12g/dL Women, &gt;13g/dL Men) at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (&gt;12g/dL women, &gt;13g/dL men) at Week 12 results for intent to treat (ITT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hb Concentration From Baseline to Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change in hemoglobin concentration from baseline to Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hb Concentration From Baseline to Week 12 in Subjects With a Baseline Hb &lt;9.5 g/dL</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change in hemoglobin concentration from baseline to Week 12 in subjects with a baseline hemoglobin &lt;9.5 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥1.0 g/dL at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Number of subjects who experience a change from baseline in hemoglobin concentration ≥1.0 g/dL at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Baseline Hb &lt;9.5g/dL That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Number of subjects with baseline hemoglobin &lt;9.5g/dL that achieve an increase in hemoglobin concentration of ≥1 g/dL at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Hb Concentration Within Normal Limits at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Normal limits defined as women with hemoglobin concentration greater than 12 g/dL and men with hemoglobin concentration greater than 13 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Baseline Hb Concentration &lt;9.5 g/dL That is Within Normal Limits at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Normal limits defined as women with hemoglobin concentration greater than 12 g/dL and men with hemoglobin concentration greater than 13 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long Term Efficacy Endpoints i.e. Proportion of Subjects Who Are Non-anaemic at 6 and 12 Months; Normalization of Ferritin Levels at 6 and 12 Months</measure>
    <time_frame>Baseline to Month 6 and Month 12</time_frame>
    <description>Long term efficacy endpoints i.e. proportion of subjects who are non-anaemic at 6 and 12 months; normalization of ferritin levels at 6 and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hb Concentration From Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in hemoglobin concentration from baseline to Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hb Concentration From Baseline to Week 4 in Subjects With a Baseline Hb &lt;9.5 g/dL</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in hemoglobin concentration from baseline to Week 4 in subjects with a baseline hemoglobin &lt;9.5 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥2.0 g/dL at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Number of subjects who experience a change from baseline in hemoglobin concentration ≥2.0 g/dL at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Baseline Hb &lt;9.5g/dL That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Number of subjects with baseline hemoglobin &lt;9.5g/dL that achieve an increase in hemoglobin concentration of ≥2 g/dL at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥1.0 g/dL at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Number of subjects who experience a change from baseline in hemoglobin concentration ≥1.0 g/dL at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Baseline Hb &lt;9.5g/dL That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Number of subjects with baseline hemoglobin &lt;9.5g/dL that achieve an increase in hemoglobin concentration of ≥1 g/dL at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Hb Concentration Within Normal Limits at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Normal limits defined as women with hemoglobin concentration greater than 12 g/dL and men with hemoglobin concentration greater than 13 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Baseline Hb Concentration &lt;9.5 g/dL That is Within Normal Limits at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Normal limits defined as women with hemoglobin concentration greater than 12 g/dL and men with hemoglobin concentration greater than 13 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥2.0 g/dL at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Number of subjects who experience a change from baseline in hemoglobin concentration ≥2.0 g/dL at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Baseline Hb &lt;9.5g/dL That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Number of subjects with baseline hemoglobin &lt;9.5g/dL that achieve an increase in hemoglobin concentration of ≥2 g/dL at Week 4</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline Physical Component and Mental Component Score</measure>
    <time_frame>Baseline to Week 52 (LOCF)</time_frame>
    <description>A multipurpose, proprietary health survey with 36 questions. It was constructed to survey health status in the Medical Outcomes Study and designed for use in clinical practice and research &amp; general population surveys.
The SF-36 includes one multi-item scale that assesses 8 health components:
Physical Functioning Component; Social Functioning Component; Role-Physical Component; Bodily Pain Component; Mental Health Component; Role-Emotional Component; Vitality Component; &amp; General Health Component.
These 8 health component scales can be further summarised into 2 summary scores, the Mental Component Score &amp; the Physical Component Score where higher values mean a better outcome.
Both scales range from 0 to 100, where higher scores indicate better health status.
The survey will be administered at study visits as indicated in the schedule of assessments, commencing pre-randomization at Visit 2. The survey will be completed by the subjects in their native language.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Treatment-emergent Adverse Events (AEs)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Number of Patients with Treatment-emergent Adverse Events (AEs).</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Treatment-emergent Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Number of Patients with Treatment-emergent Serious Adverse Events (SAEs).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Anemia, Iron-Deficiency</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Oral ferric iron compound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg capsules to be taken orally twice a day for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous iron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administered as per the local summary of product characteristics (SPC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Maltol</intervention_name>
    <arm_group_label>Oral ferric iron compound</arm_group_label>
    <other_name>Feraccru</other_name>
    <other_name>Ferric Trimaltol</other_name>
    <other_name>ST10</other_name>
    <other_name>ST10-01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Carboxy Maltose</intervention_name>
    <arm_group_label>Intravenous iron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        All of the following criteria must be met to randomize a subject in the study:

          1. Subjects must be competent to understand the information given in the Independent
             Ethics Committee (IEC) or Institutional Review Board (IRB) approved informed consent
             form and must sign and date the informed consent prior to any study mandated procedure

          2. Subjects must be willing and able to comply with study requirements

          3. Age ≥ 18 years

          4. Subjects must have a confirmed diagnosis of IBD (endoscopic and/or biopsy)

          5. Subjects must be considered suitable for intravenous iron treatment by the
             Investigator

          6. Subjects must have iron deficiency anaemia defined by the following criteria:

               1. Hb 8.0 g/dL and ≤11.0 g/dL for women OR a Hb 8.0 g/dL and ≤12.0 g/dL for men

               2. AND Ferritin &lt;30ng/ml OR Ferritin &lt;100 ng/ml WITH Transferrin saturation (TSAT)
                  &lt;20%

          7. Female subjects of childbearing potential (including perimenopausal females who have
             had a menstrual period within 1 year prior to screening) must agree to use a reliable
             method of contraception until they have completed the study and for at least 4 weeks
             following their final study visit. Reliable contraception is defined as a method which
             results in a low failure rate, i.e., less than 1% per year when used consistently and
             correctly, such as implants, injectables, some intrauterine contraceptive devices
             (IUDs), complete sexual abstinence, or a vasectomized partner. Oral contraceptive
             medications are allowed in this study. Female subjects who are surgically sterile
             (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or postmenopausal
             (defined as no menstrual period within 1 year of screening) are also allowed to
             participate.

        A subject who meets any of the following criteria is not eligible for participation in the
        study.

          1. Subject with anaemia due to any cause other than iron deficiency, including, but not
             limited to:

               1. Untreated or untreatable severe malabsorption syndrome

               2. Immunosuppressant use. Immunosuppressants are permitted so long as there is no
                  clinical evidence or suspicion of the immunosuppressant contributing to the
                  subject's anaemia or affecting erythropoiesis.

             Variations to dosing are permitted at the discretion of the investigator so long as
             there is no clinical evidence or suspicion of the immunosuppressant contributing to
             the subject's anaemia or affecting erythropoiesis

          2. Subject who has received prior to screening:

               1. Within 8 weeks intramuscular or intravenous (IV) iron or administration of depot
                  iron preparation

               2. Within 2 weeks a blood transfusion

               3. Oral iron supplementation, taken specifically to treat anaemia, within the
                  previous 4 weeks (Over the Counter (OTC) multivitamins containing iron are
                  permitted)

          3. Subjects with active inflammatory bowel disease as defined by a SCCAI score greater
             than 5 at Screening or a CDAI score greater than 300 in the Screening period (as
             assessed using the Screening haematocrit (HCT) and CDAI diary card completed by the
             subject for 7 days prior to planned randomization).

          4. Subjects with known hypersensitivity or allergy to either the active substance or
             excipients of ferric maltol capsules or ferric carboxymaltose solution for IV
             administration

          5. Subjects who have had serious adverse reactions to previous doses of ferric
             carboxymaltose or any other intravenous iron.

          6. Subjects with contraindication for treatment with iron preparations, e.g.
             hemochromatosis, chronic hemolytic disease, sideroblastic anaemia, thalassemia, or
             lead intoxication induced anaemia.

          7. Subjects with vitamin B12 or folic acid deficiency as determined by the central
             laboratory screening results. Subjects may start vitamin B12 or folate replacement and
             rescreen after at least 2 weeks.

          8. Subjects who are pregnant or breast feeding.

          9. Concomitant medical conditions with significant active bleeding likely to initiate or
             prolong anaemia.

         10. Participation in any other interventional clinical study within 30 days prior to
             screening.

         11. Subject with cardiovascular, liver, renal, haematologic, gastrointestinal,
             immunologic, endocrine, metabolic, or central nervous system disease that, in the
             opinion of the Investigator, may adversely affect the safety of the subject or
             severely limit the lifespan of the subject (i.e. unlikely to complete the full
             duration of the study).

         12. Subject with significant neurologic or psychiatric symptoms resulting in
             disorientation, memory impairment, or inability to report accurately that might
             interfere with treatment compliance, study conduct or interpretation of the results
             (e.g., Alzheimer's disease, schizophrenia or other psychosis, active or current
             alcohol or drug abuse)

         13. Subject who is an inmate of a psychiatric ward, prison, or other state institution.

         14. Subject who is an Investigator or any other team member involved directly or
             indirectly in the conduct of the clinical study.

         15. Subjects with severe renal impairment: creatinine clearance &lt;30 mL/min. (Applicable to
             US sites Only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Sampson, MBChB</last_name>
    <role>Study Director</role>
    <affiliation>Shield Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salouel</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Luneburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schweinfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2016</study_first_posted>
  <results_first_submitted>November 19, 2019</results_first_submitted>
  <results_first_submitted_qc>February 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2020</results_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iron Deficiency</keyword>
  <keyword>Anaemia</keyword>
  <keyword>Crohn's Disease</keyword>
  <keyword>Deficiency Diseases</keyword>
  <keyword>Inflammatory Bowel Diseases</keyword>
  <keyword>Intestinal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric maltol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02680756/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02680756/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 462 subjects were screened; of these, 212 subjects were not randomised (202 screening failures and 10 not assigned). 250 subjects (54% of the screened population) were randomised: 125 subjects to the ferric maltol group and 125 subjects to the IV iron group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Ferric Iron Compound</title>
          <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
        </group>
        <group group_id="P2">
          <title>Intravenous Iron</title>
          <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hb ≤7.5 g/dL</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Blood transfusion for any reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>TSAT above 60% or a ferritin above 800 m</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>None of above or not recorded</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>patient per protocol population</population>
      <group_list>
        <group group_id="B1">
          <title>Oral Ferric Iron Compound</title>
          <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
        </group>
        <group group_id="B2">
          <title>Intravenous Iron</title>
          <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="93"/>
            <count group_id="B3" value="179"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.5" spread="15.52"/>
                    <measurement group_id="B2" value="39.9" spread="15.55"/>
                    <measurement group_id="B3" value="40.2" spread="15.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age range</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.5" lower_limit="18" upper_limit="81"/>
                    <measurement group_id="B2" value="39.9" lower_limit="19" upper_limit="77"/>
                    <measurement group_id="B3" value="40.2" lower_limit="18" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian/Alaskan Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fertility status (females)</title>
          <population>This baseline measure is applicable to the female population only.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="64"/>
                    <count group_id="B3" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Sterile</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Post-menopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Potentially fertile</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Screening Hb for randomisation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;10 g/dL Female or &lt;11 g/dL Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥10 g/dL Female or ≥11 g/dL Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Hb</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;9.5 g/dL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥9.5 g/dL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IBD subgroup</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Crohn’s disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ulcerative colitis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb (&gt;12g/dL Women, &gt;13g/dL Men) at Week 12</title>
        <description>Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (&gt;12g/dL women, &gt;13g/dL men) at Week 12 results per protocol (PP)</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>results per protocol (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb (&gt;12g/dL Women, &gt;13g/dL Men) at Week 12</title>
          <description>Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (&gt;12g/dL women, &gt;13g/dL men) at Week 12 results per protocol (PP)</description>
          <population>results per protocol (PP)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb (&gt;12g/dL Women, &gt;13g/dL Men) at Week 12</title>
        <description>Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (&gt;12g/dL women, &gt;13g/dL men) at Week 12 results for intent to treat (ITT)</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>results for intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb (&gt;12g/dL Women, &gt;13g/dL Men) at Week 12</title>
          <description>Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (&gt;12g/dL women, &gt;13g/dL men) at Week 12 results for intent to treat (ITT)</description>
          <population>results for intent to treat (ITT)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hb Concentration From Baseline to Week 12</title>
        <description>Change in hemoglobin concentration from baseline to Week 12.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hb Concentration From Baseline to Week 12</title>
          <description>Change in hemoglobin concentration from baseline to Week 12.</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="1.375"/>
                    <measurement group_id="O2" value="3.00" spread="1.656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hb Concentration From Baseline to Week 12 in Subjects With a Baseline Hb &lt;9.5 g/dL</title>
        <description>Change in hemoglobin concentration from baseline to Week 12 in subjects with a baseline hemoglobin &lt;9.5 g/dL.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hb Concentration From Baseline to Week 12 in Subjects With a Baseline Hb &lt;9.5 g/dL</title>
          <description>Change in hemoglobin concentration from baseline to Week 12 in subjects with a baseline hemoglobin &lt;9.5 g/dL.</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.71" spread="1.328"/>
                    <measurement group_id="O2" value="12.90" spread="1.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥1.0 g/dL at Week 12</title>
        <description>Number of subjects who experience a change from baseline in hemoglobin concentration ≥1.0 g/dL at Week 12.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥1.0 g/dL at Week 12</title>
          <description>Number of subjects who experience a change from baseline in hemoglobin concentration ≥1.0 g/dL at Week 12.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Baseline Hb &lt;9.5g/dL That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 12</title>
        <description>Number of subjects with baseline hemoglobin &lt;9.5g/dL that achieve an increase in hemoglobin concentration of ≥1 g/dL at Week 12.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Not all subjects were tested.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Baseline Hb &lt;9.5g/dL That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 12</title>
          <description>Number of subjects with baseline hemoglobin &lt;9.5g/dL that achieve an increase in hemoglobin concentration of ≥1 g/dL at Week 12.</description>
          <population>Not all subjects were tested.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not tested</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Hb Concentration Within Normal Limits at Week 12</title>
        <description>Normal limits defined as women with hemoglobin concentration greater than 12 g/dL and men with hemoglobin concentration greater than 13 g/dL.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Hb Concentration Within Normal Limits at Week 12</title>
          <description>Normal limits defined as women with hemoglobin concentration greater than 12 g/dL and men with hemoglobin concentration greater than 13 g/dL.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Baseline Hb Concentration &lt;9.5 g/dL That is Within Normal Limits at Week 12</title>
        <description>Normal limits defined as women with hemoglobin concentration greater than 12 g/dL and men with hemoglobin concentration greater than 13 g/dL.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Baseline Hb Concentration &lt;9.5 g/dL That is Within Normal Limits at Week 12</title>
          <description>Normal limits defined as women with hemoglobin concentration greater than 12 g/dL and men with hemoglobin concentration greater than 13 g/dL.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long Term Efficacy Endpoints i.e. Proportion of Subjects Who Are Non-anaemic at 6 and 12 Months; Normalization of Ferritin Levels at 6 and 12 Months</title>
        <description>Long term efficacy endpoints i.e. proportion of subjects who are non-anaemic at 6 and 12 months; normalization of ferritin levels at 6 and 12 months.</description>
        <time_frame>Baseline to Month 6 and Month 12</time_frame>
        <population>Not all subjects were tested.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Long Term Efficacy Endpoints i.e. Proportion of Subjects Who Are Non-anaemic at 6 and 12 Months; Normalization of Ferritin Levels at 6 and 12 Months</title>
          <description>Long term efficacy endpoints i.e. proportion of subjects who are non-anaemic at 6 and 12 months; normalization of ferritin levels at 6 and 12 months.</description>
          <population>Not all subjects were tested.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <title>Non-anaemic</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Anaemic</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 52</title>
              <category_list>
                <category>
                  <title>Non-anaemic</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Anaemic</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hb Concentration From Baseline to Week 4</title>
        <description>Change in hemoglobin concentration from baseline to Week 4.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hb Concentration From Baseline to Week 4</title>
          <description>Change in hemoglobin concentration from baseline to Week 4.</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.947"/>
                    <measurement group_id="O2" value="2.15" spread="1.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hb Concentration From Baseline to Week 4 in Subjects With a Baseline Hb &lt;9.5 g/dL</title>
        <description>Change in hemoglobin concentration from baseline to Week 4 in subjects with a baseline hemoglobin &lt;9.5 g/dL.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Not all subjects were tested.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hb Concentration From Baseline to Week 4 in Subjects With a Baseline Hb &lt;9.5 g/dL</title>
          <description>Change in hemoglobin concentration from baseline to Week 4 in subjects with a baseline hemoglobin &lt;9.5 g/dL.</description>
          <population>Not all subjects were tested.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥2.0 g/dL at Week 12</title>
        <description>Number of subjects who experience a change from baseline in hemoglobin concentration ≥2.0 g/dL at Week 12.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥2.0 g/dL at Week 12</title>
          <description>Number of subjects who experience a change from baseline in hemoglobin concentration ≥2.0 g/dL at Week 12.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Baseline Hb &lt;9.5g/dL That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 12</title>
        <description>Number of subjects with baseline hemoglobin &lt;9.5g/dL that achieve an increase in hemoglobin concentration of ≥2 g/dL at Week 12.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Not all subjects were tested.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Baseline Hb &lt;9.5g/dL That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 12</title>
          <description>Number of subjects with baseline hemoglobin &lt;9.5g/dL that achieve an increase in hemoglobin concentration of ≥2 g/dL at Week 12.</description>
          <population>Not all subjects were tested.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥1.0 g/dL at Week 4</title>
        <description>Number of subjects who experience a change from baseline in hemoglobin concentration ≥1.0 g/dL at Week 4.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Total patient population for intravenous administration included subjects who did not attend Week 4 visit, therefore, the number is less than 93.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥1.0 g/dL at Week 4</title>
          <description>Number of subjects who experience a change from baseline in hemoglobin concentration ≥1.0 g/dL at Week 4.</description>
          <population>Total patient population for intravenous administration included subjects who did not attend Week 4 visit, therefore, the number is less than 93.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did not attend week 4 visit</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Baseline Hb &lt;9.5g/dL That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 4</title>
        <description>Number of subjects with baseline hemoglobin &lt;9.5g/dL that achieve an increase in hemoglobin concentration of ≥1 g/dL at Week 4.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Not all subjects were tested.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Baseline Hb &lt;9.5g/dL That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 4</title>
          <description>Number of subjects with baseline hemoglobin &lt;9.5g/dL that achieve an increase in hemoglobin concentration of ≥1 g/dL at Week 4.</description>
          <population>Not all subjects were tested.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Hb Concentration Within Normal Limits at Week 4</title>
        <description>Normal limits defined as women with hemoglobin concentration greater than 12 g/dL and men with hemoglobin concentration greater than 13 g/dL.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Total patient population for intravenous administration included subjects who did not attend Week 4 visit, therefore, the number is less than 93.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Hb Concentration Within Normal Limits at Week 4</title>
          <description>Normal limits defined as women with hemoglobin concentration greater than 12 g/dL and men with hemoglobin concentration greater than 13 g/dL.</description>
          <population>Total patient population for intravenous administration included subjects who did not attend Week 4 visit, therefore, the number is less than 93.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did not attend week 4 visit</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Baseline Hb Concentration &lt;9.5 g/dL That is Within Normal Limits at Week 4</title>
        <description>Normal limits defined as women with hemoglobin concentration greater than 12 g/dL and men with hemoglobin concentration greater than 13 g/dL.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Not all subjects were tested.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Baseline Hb Concentration &lt;9.5 g/dL That is Within Normal Limits at Week 4</title>
          <description>Normal limits defined as women with hemoglobin concentration greater than 12 g/dL and men with hemoglobin concentration greater than 13 g/dL.</description>
          <population>Not all subjects were tested.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥2.0 g/dL at Week 4</title>
        <description>Number of subjects who experience a change from baseline in hemoglobin concentration ≥2.0 g/dL at Week 4.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Total patient population for intravenous administration included subjects who did not attend Week 4 visit, therefore, the number is less than 93.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥2.0 g/dL at Week 4</title>
          <description>Number of subjects who experience a change from baseline in hemoglobin concentration ≥2.0 g/dL at Week 4.</description>
          <population>Total patient population for intravenous administration included subjects who did not attend Week 4 visit, therefore, the number is less than 93.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did not attend week 4 visit</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Baseline Hb &lt;9.5g/dL That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 4</title>
        <description>Number of subjects with baseline hemoglobin &lt;9.5g/dL that achieve an increase in hemoglobin concentration of ≥2 g/dL at Week 4</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Not all subjects were tested.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Baseline Hb &lt;9.5g/dL That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 4</title>
          <description>Number of subjects with baseline hemoglobin &lt;9.5g/dL that achieve an increase in hemoglobin concentration of ≥2 g/dL at Week 4</description>
          <population>Not all subjects were tested.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline Physical Component and Mental Component Score</title>
        <description>A multipurpose, proprietary health survey with 36 questions. It was constructed to survey health status in the Medical Outcomes Study and designed for use in clinical practice and research &amp; general population surveys.
The SF-36 includes one multi-item scale that assesses 8 health components:
Physical Functioning Component; Social Functioning Component; Role-Physical Component; Bodily Pain Component; Mental Health Component; Role-Emotional Component; Vitality Component; &amp; General Health Component.
These 8 health component scales can be further summarised into 2 summary scores, the Mental Component Score &amp; the Physical Component Score where higher values mean a better outcome.
Both scales range from 0 to 100, where higher scores indicate better health status.
The survey will be administered at study visits as indicated in the schedule of assessments, commencing pre-randomization at Visit 2. The survey will be completed by the subjects in their native language.</description>
        <time_frame>Baseline to Week 52 (LOCF)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Physical Component and Mental Component Score</title>
          <description>A multipurpose, proprietary health survey with 36 questions. It was constructed to survey health status in the Medical Outcomes Study and designed for use in clinical practice and research &amp; general population surveys.
The SF-36 includes one multi-item scale that assesses 8 health components:
Physical Functioning Component; Social Functioning Component; Role-Physical Component; Bodily Pain Component; Mental Health Component; Role-Emotional Component; Vitality Component; &amp; General Health Component.
These 8 health component scales can be further summarised into 2 summary scores, the Mental Component Score &amp; the Physical Component Score where higher values mean a better outcome.
Both scales range from 0 to 100, where higher scores indicate better health status.
The survey will be administered at study visits as indicated in the schedule of assessments, commencing pre-randomization at Visit 2. The survey will be completed by the subjects in their native language.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical component score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="7.62"/>
                    <measurement group_id="O2" value="2.5" spread="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="8.32"/>
                    <measurement group_id="O2" value="2.6" spread="7.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Treatment-emergent Adverse Events (AEs)</title>
        <description>Number of Patients with Treatment-emergent Adverse Events (AEs).</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>3 subjects were randomised to IV iron but were given ferric maltol in error.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Treatment-emergent Adverse Events (AEs)</title>
          <description>Number of Patients with Treatment-emergent Adverse Events (AEs).</description>
          <population>3 subjects were randomised to IV iron but were given ferric maltol in error.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Treatment-emergent Serious Adverse Events (SAEs)</title>
        <description>Number of Patients with Treatment-emergent Serious Adverse Events (SAEs).</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>3 subjects were randomised to IV iron but were given ferric maltol in error.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Ferric Iron Compound</title>
            <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Iron</title>
            <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Treatment-emergent Serious Adverse Events (SAEs)</title>
          <description>Number of Patients with Treatment-emergent Serious Adverse Events (SAEs).</description>
          <population>3 subjects were randomised to IV iron but were given ferric maltol in error.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The analysis of AEs focuses on TEAEs, which were defined as any AE that occurred on or worsened after the first dose of IMP and up to 14 days after the last dose of IMP (week 52 if study completed)</time_frame>
      <desc>The figures provided won't equal the total number of participants as several patients may have had the same AE.
250 patients were randomised: 125 pts in the ferric maltol group &amp; in the IV iron group each. Of these, 247 pts received at least 1 dose of IMP &amp; were included in the safety analysis. 2 pts randomised to IV were not treated: 1 pt was randomised in error &amp; was withdrawn, 1 pt withdrew consent; 1 pt randomised to FM was not treated &amp; lost to follow-up; 3 pts were given FM instead of IV.</desc>
      <group_list>
        <group group_id="E1">
          <title>Oral Ferric Iron Compound</title>
          <description>30 mg capsules to be taken orally twice a day
Ferric Maltol</description>
        </group>
        <group group_id="E2">
          <title>Intravenous Iron</title>
          <description>Administered as per the local SmPC/PI
Ferric Carboxymaltose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <description>TEAEs in &lt;2% of Subjects Overall by SOC</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Crohns disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>TEAEs in &lt;2% of Subjects Overall by SOC</description>
                <counts group_id="E1" events="69" subjects_affected="40" subjects_at_risk="127"/>
                <counts group_id="E2" events="29" subjects_affected="15" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" events="29" subjects_affected="15" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <description>TEAEs in &lt;2% of Subjects Overall by SOC</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <description>TEAEs in &lt;2% of Subjects Overall by SOC</description>
                <counts group_id="E1" events="45" subjects_affected="29" subjects_at_risk="127"/>
                <counts group_id="E2" events="32" subjects_affected="22" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <description>TEAEs in &lt;2% of Subjects Overall by SOC</description>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <description>TEAEs in &lt;2% of Subjects Overall by SOC</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <description>TEAEs in &lt;2% of Subjects Overall by SOC</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <description>TEAEs in &lt;2% of Subjects Overall by SOC</description>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <description>TEAEs in &lt;2% of Subjects Overall by SOC</description>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <description>TEAEs in &lt;2% of Subjects Overall by SOC</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>TEAEs in &lt;2% of Subjects Overall by SOC</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <description>TEAEs in &lt;2% of Subjects Overall by SOC</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Mark Sampson</name_or_title>
      <organization>Shield Therapeutics</organization>
      <phone>0207 186 8513</phone>
      <email>msampson@shieldtx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

